AB Dynamics plc (ABDP) — Investment Research Note

Executive summary

AB Dynamics designs and supplies advanced testing, simulation, and measurement products (driving robots, ADAS platforms, Suspension Parameter Measurement Machines and driving simulators) plus testing services to global automotive OEMs, Tier 1s and NCAP bodies. From FY24 to FY26 the business has moved from double-digit growth (+10% FY24, +3% FY25) to a material contraction — the July 2026 profit warning cut FY26 continuing-operations revenue guidance to £90-95m, alongside the exit of the loss-making Chinese VadoTech services business (a £16.8m impairment in H1 FY26). The single most important valuation point today: the shares have fallen from 1,465p to 781p (-47% in ~12 months) while structural drivers (ADAS regulation, NCAP protocols, autonomy testing) remain intact and the balance sheet still holds £41.7m of net cash — the market has repriced ABDP as if the structural story is broken, but the filings suggest a cyclical/execution downturn, not a terminal one.

Fair value estimate

Methodology: blended EV/EBIT multiple on FY27E "normalised" operating profit plus explicit balance sheet.

Key assumptions:

• FY26E continuing-ops revenue £92m mid-point; adjusted operating profit ~£18m (20% margin per management guidance) 2026-07 trading update
• FY27E revenue recovery to ~£100-105m as order intake normalises (order book £47m at H1 FY26 remains healthy) 2026-04 H1 report
• FY27E adjusted operating profit £20-22m (20-21% margin) — consistent with management's medium-term >20% margin ambition and 10% organic growth target 2025-11 final results
• eMpulse acquisition adds ~£6-8m revenue in FY27 with modest profit contribution 2026-08 acquisition RNS
• EV/EBIT multiple range 11x-14x — a discount to specialised test-equipment peers (Judges, Spectris, Halma trade 15-25x) reflecting current execution noise and CFO transition
• Add net cash ~£40m (FY26 year-end estimate — H2 working capital unwind expected)

Central case:

• FY27E adj. operating profit ~£21m × 12.5x = EV £263m
• • net cash ~£40m = Equity value £303m
• ÷ 22.9m shares = 1,320p per share

Fair value range: 1,050p – 1,500p per share (implied market cap £240m – £344m)

Compared to current price 781p / market cap £188m:

• Absolute upside vs mid-point (1,275p): +63%
• Low end (1,050p): +34%
• High end (1,500p): +92%

Sector context

Formally classified under Automobiles and Parts, but this misclassifies the business — ABDP is really a specialised test-equipment / scientific-instruments company serving the auto R&D end market. Quality profile (60%+ gross margins, 20%+ operating margins, 100%+ cash conversion, net cash) is materially above typical autos peers and closer to precision-instruments compounders. Relevant listed peers: Spectris (SXS), Halma (HLMA), Judges Scientific (JDG). All trade on notably higher multiples than ABDP does today.

Investment thesis

• Structural regulatory tailwinds are intact: Euro NCAP 2026 protocols will add tests taking scenarios to >1,000; US mandate for Automatic Emergency Braking on all light-duty vehicles by 2029 drives ongoing OEM investment in ADAS test capacity. ABDP is the market-leading supplier of driving robots and ADAS platforms; growth is largely regulation-driven rather than OEM-volume driven 2026-04 H1 report.
• Sell-off has created valuation asymmetry: shares are down 47% in a year on cyclical order-timing issues and the isolated VadoTech write-off. On FY27E normalised earnings the EV/EBIT multiple (~7x post-cash) is roughly half what specialised instrument peers trade on, despite ROCE of 21.2% and 100%+ cash conversion 2026-04 H1 report; 2025-11 final results.
• Fortress balance sheet with optionality: £41.7m net cash + £20m undrawn RCF, ongoing acquisition pipeline (eMpulse just added for $11m + earn-out), progressive dividend growing 10-20% p.a. through the downturn — signals Board confidence and provides downside cushion 2026-07 trading update; 2026-08 eMpulse acquisition.

Key risks

• Auto-cycle exposure with European OEM stress: several European OEMs restructuring, order conversion timelines lengthening; if the cyclical downturn extends into FY27, revenue could stay below £100m for longer, deferring the operating-leverage recovery 2026-07 trading update.
• Execution / leadership instability: CEO transition (Sarah Matthews-DeMers replacing James Routh Dec 2025), plus an Interim CFO (Andrew Lewis, Feb 2026); permanent CFO not yet named. Combined with the VadoTech misstep (bought Mar 2021, impaired 5 years later at cost of £16.8m), this raises questions about capital allocation and management bandwidth 2026-04 H1 report; 2026-07 trading update.
• Testing-services commoditisation risk: VadoTech showed how service-based revenue can be structurally repriced by a single OEM customer. Recent acquisitions (Venshure, Bolab, eMpulse) all involve earn-outs — integration and performance-payment risk is elevated 2026-04 H1 report; 2026-08 eMpulse.

Operating leverage

ABDP has meaningful — though not extreme — operating leverage. Gross margins are structurally 60%+ (H1 FY26: 63.7%, up 350bps despite -16% revenue) which is atypical for an "industrial" and characteristic of a scaled fixed-cost R&D / IP-heavy model. In H1 FY26 the group held the adjusted operating margin flat at 18.6% despite the revenue drop — evidence that management can flex costs, but also evidence that the incremental drop-through on the way back up will be significant. Head-office unallocated costs (~£2m/half-year) don't scale; group R&D and 14 facilities create a fixed base. Rough sensitivity: at management's medium-term revenue framework, a 10-20% revenue beat above FY26 exit rates would likely add 40-60% to operating profit (i.e. going from £18m to £26-29m on a £100-108m revenue base at 25-27% incremental margin). The FY25 result illustrated this: 3% revenue growth translated to 15% adj. operating profit growth and 210bps margin expansion 2025-11 final results; 2026-04 H1 report.

Value-trap signals

• Single-customer commoditisation in VadoTech — an example of how OEM contracts can be repriced away; the write-off is now taken but signals contract fragility in services.
• CEO and CFO transitions overlapping the profit warning — the risk of further "kitchen sinking" in FY26 statutory results is non-trivial.
• Deceleration is real not just optical — the trading update explicitly cites lengthening customer procurement timelines and European OEM restructuring; this is a demand-side headwind, not just phasing.

Not sufficient in aggregate to call it a structural value trap: recurring revenue, quality customer base (>150 OEMs), regulatory tailwinds, and balance sheet all provide durability. But investors should size accordingly.

Earnings vs. expectations

• FY25 (Nov 2025): guided ~£22.3m adj. operating profit → delivered £23.3m → beat (~4-5% ahead).
• FY24 (Nov 2024): guided FY25 outlook "slightly ahead of expectations" (£21.5m consensus) → subsequently delivered.
• H1 FY26 (Apr 2026): in line with expectations, maintained FY26 guidance of £24.4m.
• Jul 2026 trading update: materially cut FY26 revenue guidance to £90-95m from continuing operations (vs implied ~£120m prior); FY26 adj. op profit implicitly cut to ~£18m (20% margin on £92m) vs £24.4m consensus — material miss / profit warning.

Pattern: management historically delivered slightly ahead of guidance, but the July 2026 warning is a clear break from that pattern and represents the first meaningful miss in the filings shown. This weakens the "management always beats" narrative and justifies a discount vs. peer multiples until a track record is re-established.

Conviction

Conviction: 3 (moderate)

Anchoring factors: (i) clear, consistent, well-disclosed non-GAAP framework with reconciliations; (ii) multiple valuation approaches (EV/EBIT, trailing P/E, EV/sales) all suggest the shares are cheap to fair; (iii) balance sheet and cash conversion provide a hard floor.

Limiting factors: (i) FY26/FY27 revenue trajectory has meaningfully uncertainty given the recent profit warning and European OEM disruption — the operating-profit "normalised" number I'm using could easily be 15-20% off in either direction; (ii) permanent CFO not yet appointed, so full clarity on capital allocation / M&A pace is limited.